Theradiag: Substantial Potential Reduction in Treatment Costs Thanks to Biotherapy Monitoring

Regulatory News:

THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, today announces that

a systematic review of the pharmaco-economic studies¹ published in the Journal of Gastroenterology shows that the monitoring of biotherapies in the treatment of inflammatory diseases allows biotherapy treatment costs to be reduced by between 28 and 34% in controlled trials.

This systematic review, undertaken by Professor Laurent Peyrin-Biroulet of Nancy University Hospital, focused on published studies in the field of chronic inflammatory bowel disease and rheumatoid arthritis on patients showing a loss of therapeutic response or in remission.

"Every impact assessment study on the savings generated by the monitoring of biotherapies in gastroenterology and rheumatology have shown that the pharmacological dosage strategy results in substantial savings with regard to the cost of the drug without affecting the treatment’s efficacy”, says Professor Laurent Peyrin-Biroulet.

These results were obtained using different mathematical models or during randomized controlled trials, and covered various European and American health systems.

"This study supports the pharmaco-economic study undertaken in October 2014 that showed that the monitoring of biotherapies allowed the cost of treating Crohn’s disease in resistant patients in secondary failure of treatment by infliximab, to be reduced by up to 25%, representing potential savings of 130 million euros over 5 years over 10,000 patients.”, comments Professor Gérard Tobelem, Chairman of Theradiag’s Board of Directors.

About Theradiag
Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa Tracker® range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of rectal cancer, auto-immune and inflammatory diseases and HIV/AIDS. Theradiag is thus participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 75 employees.

For more information about Theradiag, please visit our website: www.theradiag.com

¹ https://www.ncbi.nlm.nih.gov/pubmed/27665099

View source version on businesswire.com: http://www.businesswire.com/news/home/20161010005673/en/